Antibody response against GD2 after vaccination with increasing doses of GD2L in a GD2L-KLH plus QS-21 vaccine
| Patient no. (dose) . | ELISA with GD2 Reciprocal peak titera . | . | FACS with NMB-7 % positive cells (MFI)b . | . | . | . | CDC with NMB-7 % cytotoxicityc . | ITLCd . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | IgM . | IgG . | IgM . | . | IgG . | . | . | . | . | . | ||||||
| . | Post . | Post . | Pre . | Post . | Pre . | Post . | . | Pooled gangliosidese . | Sarcoma extract . | 0.5 μg GD2 . | ||||||
| 3 μg | ||||||||||||||||
| 1 | 20 | 20 | 10 (20) | 16 (21) | 11 (6) | 10 (5) | 12 | |||||||||
| 2 | 320 | 0 | 10 (10) | 98 (42) | 11 (6) | 17 (9) | 86 | |||||||||
| 3 | 40 | 160 | 10 (13) | 6 (7) | 11 (5) | 10 (5) | 2 | |||||||||
| 4 | 80 | 80 | 10 (6) | 12 (7) | 10 (5) | 8 (5) | 3 | |||||||||
| 5 | 80 | 80 | 11 (7) | 20 (9) | 10 (5) | 9 (6) | 28 | |||||||||
| 6 | 160 | 80 | 10 (15) | 8 (14) | 10 (6) | 12 (5) | 46 | |||||||||
| 10 μg | ||||||||||||||||
| 7 | 2560 | 80 | 10 (95) | 38 (205) | 10 (10) | 9 (10) | 70 | |||||||||
| 8 | 320 | 40 | 10 (91) | 15 (119) | 10 (7) | 7 (7) | 40 | |||||||||
| 9 | 320 | 160 | 10 (43) | 53 (113) | 10 (7) | 9 (8) | 98 | |||||||||
| 10 | 160 | 320 | 9 (60) | 13 (72) | 12 (7) | 18 (9) | 0 | |||||||||
| 11 | 40 | 320 | 10 (66) | 21 (65) | 9 (7) | 8 (6) | 0 | |||||||||
| 12 | 320 | 80 | 10 (52) | 73 (150) | 9 (7) | 13 (8) | 10 | |||||||||
| 30 μg | ||||||||||||||||
| 13 | 1280 | 80 | 10 (90) | 92 (352) | 10 (8) | 11 (8) | 67 | +++ | + | +++ | ||||||
| 14 | 80 | 80 | 10 (46) | 56 (98) | 10 (6) | 10 (6) | 27 | ++ | + | ++ | ||||||
| 15 | 640 | 640 | 10 (61) | 70 (135) | 10 (8) | 37 (11) | 42 | +++ | ++ | +++ | ||||||
| 16f | 320 | 0 | 10 (63) | 50 (132) | 10 (8) | 16 (14) | 32 | +++ | ++ | +++ | ||||||
| 17 | 2560 | 160 | 10 (60) | 88 (287) | 9 (6) | 17 (8) | 45 | +++ | +++ | +++ | ||||||
| 18 | 20 | 0 | 10 (71) | 19 (112) | 10 (9) | 9 (8) | 7 | − | − | − | ||||||
| Patient no. (dose) . | ELISA with GD2 Reciprocal peak titera . | . | FACS with NMB-7 % positive cells (MFI)b . | . | . | . | CDC with NMB-7 % cytotoxicityc . | ITLCd . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | IgM . | IgG . | IgM . | . | IgG . | . | . | . | . | . | ||||||
| . | Post . | Post . | Pre . | Post . | Pre . | Post . | . | Pooled gangliosidese . | Sarcoma extract . | 0.5 μg GD2 . | ||||||
| 3 μg | ||||||||||||||||
| 1 | 20 | 20 | 10 (20) | 16 (21) | 11 (6) | 10 (5) | 12 | |||||||||
| 2 | 320 | 0 | 10 (10) | 98 (42) | 11 (6) | 17 (9) | 86 | |||||||||
| 3 | 40 | 160 | 10 (13) | 6 (7) | 11 (5) | 10 (5) | 2 | |||||||||
| 4 | 80 | 80 | 10 (6) | 12 (7) | 10 (5) | 8 (5) | 3 | |||||||||
| 5 | 80 | 80 | 11 (7) | 20 (9) | 10 (5) | 9 (6) | 28 | |||||||||
| 6 | 160 | 80 | 10 (15) | 8 (14) | 10 (6) | 12 (5) | 46 | |||||||||
| 10 μg | ||||||||||||||||
| 7 | 2560 | 80 | 10 (95) | 38 (205) | 10 (10) | 9 (10) | 70 | |||||||||
| 8 | 320 | 40 | 10 (91) | 15 (119) | 10 (7) | 7 (7) | 40 | |||||||||
| 9 | 320 | 160 | 10 (43) | 53 (113) | 10 (7) | 9 (8) | 98 | |||||||||
| 10 | 160 | 320 | 9 (60) | 13 (72) | 12 (7) | 18 (9) | 0 | |||||||||
| 11 | 40 | 320 | 10 (66) | 21 (65) | 9 (7) | 8 (6) | 0 | |||||||||
| 12 | 320 | 80 | 10 (52) | 73 (150) | 9 (7) | 13 (8) | 10 | |||||||||
| 30 μg | ||||||||||||||||
| 13 | 1280 | 80 | 10 (90) | 92 (352) | 10 (8) | 11 (8) | 67 | +++ | + | +++ | ||||||
| 14 | 80 | 80 | 10 (46) | 56 (98) | 10 (6) | 10 (6) | 27 | ++ | + | ++ | ||||||
| 15 | 640 | 640 | 10 (61) | 70 (135) | 10 (8) | 37 (11) | 42 | +++ | ++ | +++ | ||||||
| 16f | 320 | 0 | 10 (63) | 50 (132) | 10 (8) | 16 (14) | 32 | +++ | ++ | +++ | ||||||
| 17 | 2560 | 160 | 10 (60) | 88 (287) | 9 (6) | 17 (8) | 45 | +++ | +++ | +++ | ||||||
| 18 | 20 | 0 | 10 (71) | 19 (112) | 10 (9) | 9 (8) | 7 | − | − | − | ||||||
ELISA titers 1:40 and above are consider positive.
mAb 3F8 used as a positive control for FACS and CDC, it showed >90% positive cells and 75% lysis, respectively. MFI, mean fluorescence intensity.
Specific chromium release after immunization minus specific chromium release before immunization.
Only 30-μg dose tested by ITLC. The TLC immune reaction was graded as − (negative), + (weakly positive), ++ (positive) and +++ (strongly positive).
Pooled gangliosides are GD2, GD3, GM2, and GM3.
Patient 16 received only four vaccines.